Feature | October 15, 2014

Imricor Announces First Procedures in Clinical Study of MR-Enabled Cardiac Ablation Products

Up to 15 patients will be enrolled in United Kingdom study

October 15, 2014 — Imricor Medical Systems, Inc. announced the first three cardiac ablation procedures were completed in the first clinical study that is evaluating the feasibility of their magnetic resonance (MR)-enabled products to treat atrial flutter. Prof. Reza Razavi, head of the Division of Imaging Sciences and Biomedical Engineering, King's College London, is the principal investigator for the study and performed the procedures along with Mark O'Neill, professor of cardiac electrophysiology and consultant cardiologist, Guy's and St. Thomas' NHS Trust in the United Kingdom, The prospective pilot study will enroll up to 15 patients at this center.

The Vision-MR Ablation Catheter and Advantage-MR EP Recorder/Stimulator System are currently being evaluated for the treatment of atrial flutter. The Vision-MR Ablation Catheter looks, feels and functions like a conventional ablation catheter. The Advantage-MR EP Recording/Stimulator System is also MR-enabled to avoid dangerous electromagnetic interactions with the MRI scanner and provide clear intra-cardiac electrograms and interference-free MR images. The system delivers the needed MR-enabled recording and pacing functions. Both products are used in conjunction with the iSuite image guidance platform that is provided by Philips.

"There have been many technical advances that have gone into this technology in order to create a system suitable for clinical use, and it has performed extremely well in the early phases of clinical trials. This is a groundbreaking study and we believe that there is a great future for MR-guided heart rhythm interventions. Not only is the requirement for X-rays removed, but for the first time the clinician is able to see the detailed anatomy of the heart, in real-time, during the procedure, and the therapeutic ablation lesions that have been created. The impact that such information could have on complex ablation procedures is enormous. We hope that this is a great step forward in the care and treatment of patients with abnormal heart rhythms," said Razavi.

For more information: www.imricor.com

Related Content

AAPM 2019 Features More Than 40 Presentations on ViewRay's MRIdian MRI-guided Radiotherapy
News | Image Guided Radiation Therapy (IGRT) | July 16, 2019
ViewRay Inc. announced that the company's MRIdian System is the focus of more than 40 abstracts selected by the...
FDA Approves Bayer's Gadavist Contrast for Cardiac MRI in Adult Coronary Artery Disease Patients
Technology | Contrast Media | July 15, 2019
The U.S. Food and Drug Administration (FDA) has approved Gadavist injection for use in cardiac magnetic resonance...
Insightec's Exablate Neuro Approved With GE Signa Premier MRI in U.S. and Europe
News | Focused Ultrasound Therapy | July 10, 2019
GE Healthcare and Insightec announced U.S. Food and Drug Administration (FDA) approval and CE mark for Insightec’s...
Delta T1 Maps Provide Quantitative, Automated Solution to Assess Brain Tumor Burden
News | Neuro Imaging | July 05, 2019
Imaging Biometrics LLC (IB) a subsidiary of IQ-AI Ltd., is highlighting a recently published study in the American...
Medic Vision Wins Japanese PMDA Clearance for iQMR Image Reconstruction Solution
News | Magnetic Resonance Imaging (MRI) | July 05, 2019
Medic Vision Imaging Solutions announced that its 3-D iterative image reconstruction technology for shortening magnetic...
Bay Labs Announces New Echocardiography Guidance Software Data at ASE 2019 Scientific Sessions
News | Cardiovascular Ultrasound | June 20, 2019
Bay Labs announced that new data on the company’s first-of-its-kind deep learning investigational guidance software...
LVivo EF Comparable to MRI, Contrast Echo in Assessing Ejection Fraction
News | Cardiovascular Ultrasound | June 19, 2019
DiA Imaging Analysis announced the presentation of two studies assessing the performance and accuracy of the company's...
New Data Demonstrates Safety Profile of GammaTile Therapy for Various Brain Tumors
News | Brachytherapy Systems | June 18, 2019
GT Medical Technologies Inc. announced the presentation of clinical data from a prospective study of GammaTile Therapy...
Black Men Less Likely to Adopt Active Surveillance for Low-Risk Prostate Cancer
News | Prostate Cancer | June 17, 2019
A new study reveals black men are less likely than white men to adopt an active surveillance strategy for their...